Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) EPS (Basic) (2019 - 2025)

Goldenwell Biotech's EPS (Basic) history spans 7 years, with the latest figure at -$0.0 for Q3 2025.

  • For Q3 2025, EPS (Basic) rose 66.28% year-over-year to -$0.0; the TTM value through Sep 2025 reached -$0.0, down 162.16%, while the annual FY2024 figure was -$0.0, 9.14% down from the prior year.
  • EPS (Basic) reached -$0.0 in Q3 2025 per GWLL's latest filing, up from -$0.0 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.0 in Q4 2024 to a low of -$0.01 in Q4 2022.
  • Average EPS (Basic) over 5 years is -$0.0, with a median of -$0.0 recorded in 2024.
  • Peak YoY movement for EPS (Basic): crashed 14209.11% in 2021, then soared 418.3% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at -$0.0 in 2021, then tumbled by 2849.02% to -$0.01 in 2022, then skyrocketed by 97.74% to -$0.0 in 2023, then skyrocketed by 418.3% to $0.0 in 2024, then crashed by 111.75% to -$0.0 in 2025.
  • Per Business Quant, the three most recent readings for GWLL's EPS (Basic) are -$0.0 (Q3 2025), -$0.0 (Q2 2025), and -$0.0 (Q1 2025).